Holly C. Rickman

Array ( [id] => 20032035 [patent_doc_number] => 20250170257 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-05-29 [patent_title] => HUMANIZED ANTI-TISSUE FACTOR ANTIBODY, ANTIBODY-DRUG CONJUGATE PREPARED THEREFROM AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 19/043567 [patent_app_country] => US [patent_app_date] => 2025-02-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 2439 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 60 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19043567 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19982862 [patent_doc_number] => 20250121084 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-04-17 [patent_title] => ANTI-CLAUDIN-6 CONJUGATES [patent_app_type] => utility [patent_app_number] => 18/971848 [patent_app_country] => US [patent_app_date] => 2024-12-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9126 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 188 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18971848 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20048382 [patent_doc_number] => 20250186604 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-06-12 [patent_title] => ANTI-PSMA ANTIBODY CONJUGATES [patent_app_type] => utility [patent_app_number] => 18/969940 [patent_app_country] => US [patent_app_date] => 2024-12-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6613 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 218 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18969940 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19744068 [patent_doc_number] => 20250032633 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-01-30 [patent_title] => ANTIBODY-DRUG CONJUGATE AND APPLICATION THEREOF [patent_app_type] => utility [patent_app_number] => 18/910550 [patent_app_country] => US [patent_app_date] => 2024-10-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15347 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 158 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18910550 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19657063 [patent_doc_number] => 20240424128 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-12-26 [patent_title] => HUMANIZED ANTIBODIES AGAINST NECTIN-2 AND DRUG CONJUGATES THEREOF [patent_app_type] => utility [patent_app_number] => 18/818412 [patent_app_country] => US [patent_app_date] => 2024-08-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13149 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 136 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18818412 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19571934 [patent_doc_number] => 20240376226 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-11-14 [patent_title] => COMPOSITIONS AND METHODS RELATING TO TUMOR ACTIVATED T CELL ENGAGERS [patent_app_type] => utility [patent_app_number] => 18/785900 [patent_app_country] => US [patent_app_date] => 2024-07-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 54752 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 120 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18785900 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19556473 [patent_doc_number] => 20240368265 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-11-07 [patent_title] => Methods of Treating Crohn's Disease with Anti-IL23 Specific Antibody [patent_app_type] => utility [patent_app_number] => 18/765663 [patent_app_country] => US [patent_app_date] => 2024-07-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 50887 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -24 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18765663 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19543190 [patent_doc_number] => 20240360226 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-10-31 [patent_title] => ANTIBODY MOLECULES AND CONJUGATES [patent_app_type] => utility [patent_app_number] => 18/753316 [patent_app_country] => US [patent_app_date] => 2024-06-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 43578 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -38 [patent_words_short_claim] => 18 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18753316 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19745697 [patent_doc_number] => 20250034262 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-01-30 [patent_title] => ANTI-MICA/B ANTIBODIES THAT BLOCK MICA/B SHEDDING AND METHODS OF USE [patent_app_type] => utility [patent_app_number] => 18/751276 [patent_app_country] => US [patent_app_date] => 2024-06-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 34936 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 40 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18751276 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20129206 [patent_doc_number] => 12371508 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-07-29 [patent_title] => Binding agents targeting TROP2-expressing tumor cells [patent_app_type] => utility [patent_app_number] => 18/664078 [patent_app_country] => US [patent_app_date] => 2024-05-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 55 [patent_figures_cnt] => 100 [patent_no_of_words] => 87957 [patent_no_of_claims] => 28 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 57 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18664078 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19543206 [patent_doc_number] => 20240360242 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-10-31 [patent_title] => BINDING AGENTS TARGETING TROP2-EXPRESSING TUMOR CELLS [patent_app_type] => utility [patent_app_number] => 18/620397 [patent_app_country] => US [patent_app_date] => 2024-03-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 91655 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18620397 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19563562 [patent_doc_number] => 12138313 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-11-12 [patent_title] => Anti-cub domain-containing protein 1 (CDCP1) antibodies, antibody drug conjugates, and methods of use thereof [patent_app_type] => utility [patent_app_number] => 18/612088 [patent_app_country] => US [patent_app_date] => 2024-03-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 53 [patent_figures_cnt] => 55 [patent_no_of_words] => 71280 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 56 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18612088 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19380998 [patent_doc_number] => 20240270868 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-08-15 [patent_title] => ANTI-CUB DOMAIN-CONTAINING PROTEIN 1 (CDCP1) ANTIBODIES, ANTIBODY DRUG CONJUGATES, AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 18/612866 [patent_app_country] => US [patent_app_date] => 2024-03-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 71281 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18612866 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20143998 [patent_doc_number] => 12378326 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-08-05 [patent_title] => Anti-CD28 x anti-PSMA antibodies [patent_app_type] => utility [patent_app_number] => 18/440860 [patent_app_country] => US [patent_app_date] => 2024-02-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 173 [patent_figures_cnt] => 189 [patent_no_of_words] => 95847 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 49 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18440860 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19265408 [patent_doc_number] => 20240209107 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-06-27 [patent_title] => CD28/OX40 BISPECIFIC ANTIBODIES [patent_app_type] => utility [patent_app_number] => 18/543673 [patent_app_country] => US [patent_app_date] => 2023-12-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 31396 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -24 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18543673 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19961641 [patent_doc_number] => 12331125 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-06-17 [patent_title] => Anti-cMet antibody-drug conjugates and uses thereof [patent_app_type] => utility [patent_app_number] => 18/510256 [patent_app_country] => US [patent_app_date] => 2023-11-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 18 [patent_figures_cnt] => 20 [patent_no_of_words] => 124580 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 247 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18510256 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18879163 [patent_doc_number] => 20240002532 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-01-04 [patent_title] => CHIMERIC ANTIGEN RECEPTOR FOR TUMOR TARGETING [patent_app_type] => utility [patent_app_number] => 18/346130 [patent_app_country] => US [patent_app_date] => 2023-06-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11913 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 178 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18346130 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20401296 [patent_doc_number] => 12491256 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-12-09 [patent_title] => Anti-cub domain-containing protein 1 (CDCP1) antibodies, antibody drug conjugates, and methods of use thereof [patent_app_type] => utility [patent_app_number] => 18/320885 [patent_app_country] => US [patent_app_date] => 2023-05-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 53 [patent_figures_cnt] => 55 [patent_no_of_words] => 65736 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 169 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18320885 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20256152 [patent_doc_number] => 12428495 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-09-30 [patent_title] => Antibodies against YKL-40 and uses thereof [patent_app_type] => utility [patent_app_number] => 18/140972 [patent_app_country] => US [patent_app_date] => 2023-04-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 9 [patent_no_of_words] => 14667 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 206 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18140972 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18657739 [patent_doc_number] => 20230303693 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-09-28 [patent_title] => BISPECIFIC ANTIBODY AGAINST CD3 AND CD20 IN COMBINATION THERAPY FOR TREATING DIFFUSE LARGE B-CELL LYMPHOMA [patent_app_type] => utility [patent_app_number] => 18/160391 [patent_app_country] => US [patent_app_date] => 2023-01-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 26887 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18160391 [rel_patent_id] =>[rel_patent_doc_number] =>)